Mazdutide is developed for the treatment of obesity and  type 2 diabetes. It is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor. This means it activates both receptors, which are involved in regulating appetite, metabolism, and glucose control.